Cardiovascular toxicity is the most common cause of fatality in the first 24 hours of poisoning with aluminium phosphide (AlP). Most often manifesting itself in cardiac dysrhythmias. The aim of this study was to evaluate the benefits of amiodarone prophylaxis against cardiac dysrhythmia in 46 patients with acute AlP poisoning. They were divided in two groups of 23: one receiving amiodarone and the other not (control). The treatment group received amiodarone prophylaxis in the initial intravenous bolus dose of 150 mg, followed by a drip of 1 mg/min for six hours and then of 0.5 mg/min for eighteen hours. Both groups were Holter-monitored for 24 hours since admission. Save for amiodarone, both groups received the same standard treatment. Amiodarone had a significant beneficial effect in reducing the frequency of STsegment elevation and ventricular fibrillation plus atrial fibrillation (P=0.02 and P=0.01, respectively), but the groups did not differ significantly in mortality (9 vs 11 patients, respectively). The mean time between ICU admission and death (survival time) was significantly longer in the treatment group (22 vs 10 h, respectively; P=0.03). Regardless its obvious limitations, our study suggests that even though amiodarone alone did not reduce mortality, it may provide enough time for antioxidant therapy to tip the balance in favour of survival and we therefore advocate its prophylactic use within the first 24 h of AlP poisoning.
Aluminium phosphide (AlP) is used in agriculture due to low cost and high efficacy as a fumigant pesticide. Acute AlP poisoning is mainly reported in Asian countries like India and Iran (1-3) and is the most common cause of death among pesticides, with a mortality rate of 31% to 77% (2-6).
Signs and symptoms of acute AlP poisoning include gastrointestinal, cardiovascular, hepatic, renal, and neurologic (1). Most of the deaths occur within the first 24 hours after ingestion due to cardiovascular involvement, dysrhythmias such as ventricular tachycardia (VT), ventricular fibrillation (VF), supra-ventricular tachycardia (SVT), and atrial flutter and fibrillation (AF) in particular (7) (8) (9) (10) .
Amiodarone is an antidysrhythmic used to treat SVT and ventricular tachydysrhythmia, by blocking repolarisation and prolonging the refractory period of the myocardium, which prevents tachydysrhythmia. It is associated with improved survival in non-ischaemic cardiomyopathy but not in post-myocardial infarction, yet its use in postmyocardial infarction and congestive heart failure patients is safe (11, 12) . Amiodarone also improves survival in patients with AF by effectively converting AF to sinus rhythm and maintaining it after conversion (12) .
For all these reasons, the aim of this study was to evaluate its potential as prophylaxis against AlP-induced dysrhythmia.
SUBJECTS AND METHODS

Study population
This was a prospective, randomised, controlled, open label clinical trial in patients with acute AlP poisoning. The study included 46 patients older than 12 years admitted to the Medical Toxicology Intensive Care Unit (MT ICU) of the Loghman Hakim Hospital Poison Center, Tehran, Iran over six months. Patients with the history of diabetes mellitus, cardiovascular, respiratory, renal, and hepatic failure, substance abuse, co-ingestion, advanced medical management for poisoning, and antidysrhythmic therapy started elsewhere before admission were excluded from the study.
The diagnosis was based on the history of exposure, clinical manifestations, and positive silver nitrate test on exhaled breath or stomach content samples. The study was approved by the Ethics Committee of the Shahid Beheshti University of Medical Sciences in Tehran and observed the Declaration of Helsinki.
Treatment protocol
The treatment started with gastric decontamination in the Emergency Department, followed by immediate admission to the ICU and management based on the same standard protocol for all patients (4-6 g of magnesium sulphate and 4 g of calcium gluconate by intravenous (IV) infusion daily and adequate hydration), except for amiodarone treatment. IV infusion of 10 µg/min norepinephrine was administered as required. All the patients were treated under the supervision of the same physicians and nurses.
The patients were randomised in two groups: those with even file number were assigned to the treatment group receiving amiodarone prophylaxis (n=23) and those with the odd file number were assigned to control (not receiving amiodarone) (n=23).
The initial loading dose of 150 mg was given as IV bolus, followed by IV infusions of 1 mg/min for six hours and then of 0.5 mg/min for another 18 hours, as described elsewhere (13) . Both groups were monitored with a 24-hour Holter from admission to the ICU or until the time of death if it occurred within the first 24 h. Holter records were then given to a cardiologist blind to the treatment and control groups for interpretation. All the patients were followed up until discharge from the hospital or death.
Patient information about sex, age, cause of poisoning, ingested AlP dose, time between ingestion and ICU admission, clinical manifestations and paraclinical findings on admission time, duration of hospitalisation, and outcome were taken from the patients' medical files. All information was kept confidential during the study.
Statistical analysis
The data were expressed as mean ± standard deviation (SD), frequency, and ratio and analysed with SPSS version 16 (SPSS Inc., Chicago, IL, USA). Qualitative variables were compared with the chi-square test, and quantitative variables were tested for normality of distribution with the Kolmogorov-Smirnov test. Variables with normal distribution were further tested with Student's t-test and others with the Mann-Whitney U-test. P values of 0.05 or less were considered statistically significant. 
RESULTS
In 45 of the 46 cases poisoning was intentional, and 20 patients died (ratio 0.435). Table 1 shows the demographic, clinical and laboratory data for both groups on admission to the ICU. Table 2 compares the frequencies of dysrhythmias registered by the Holter between the groups. Amiodarone significantly lowered the occurrence of ST-segment elevation and VF+AF.
The need for the administration of vasopressor norepinephrine and mortality did not significantly differ between the treatment and control group [12 vs 13 patients (P=1) for norepinephrine and 9 vs 11 patients for mortality (P=0.8), respectively].
Median time elapsed between ICU admission and death (survival time) was 23 h (range: 16-28) in the treatment group and 10 h (range: 6-14) in the control group (P<0.001) (Figure 1) .
DISCUSSION
To the best of our knowledge there are only two studies on IV administration of amiodarone in acute AlP poisoning, and one reported no VT response to treatment (14) and the other reported very limited beneficial effects (15) . Even though amiodarone prophylaxis in our study significantly decreased the occurrence of AF+VF and ST-segment elevation and significantly increased survival time, it did not reduce mortality. However, interpretation of our results is quite limited by the small sample.
Another limitation of our study is that we did not observe or treat myocardial oxidative damage, whereas other studies showed significant beneficial effects of antioxidants against cardiovascular toxicity (16) (17) (18) . Future studies should therefore combine amiodarone and antioxidant treatment.
Even though amiodarone alone did not reduce mortality, it may provide enough time for antioxidant therapy to tip the balance in favour of survival and we therefore advocate its prophylactic use within the first 24 h of AlP poisoning.
